研究单位:[1]Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China[2]Chongqing Precision Biotech Co., Ltd
This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.